GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) today announced the company plans to participate in the Canaccord Genuity Medical Technologies & Diagnostics Forum in New York, NY.
Senseonics’ management is scheduled to present on Thursday, November 9, 2017 at 11:00 AM ET. Interested parties may access a webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ first generation CGM system, Eversense®, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels. For more information on Senseonics, please visit www.senseonics.com.